Literature DB >> 17050781

Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants.

Sevasti B Koukouritaki1, Mark T Poch, Marilyn C Henderson, Lisbeth K Siddens, Sharon K Krueger, Jonathan E VanDyke, David E Williams, Nicholas M Pajewski, Tao Wang, Ronald N Hines.   

Abstract

Flavin-containing monooxygenases (FMOs) are important for the disposition of many therapeutics, environmental toxicants, and nutrients. FMO3, the major adult hepatic FMO enzyme, exhibits significant interindividual variation. Eighteen FMO3 single-nucleotide polymorphism (SNP) frequencies were determined in 202 Hispanics (Mexican descent), 201 African Americans, and 200 non-Latino whites. Using expressed recombinant enzyme with methimazole, trimethylamine, sulindac, and ethylenethiourea, the novel structural variants FMO3 E24D and K416N were shown to cause modest changes in catalytic efficiency, whereas a third novel variant, FMO3 N61K, was essentially devoid of activity. The latter variant was present at an allelic frequency of 5.2% in non-Latino whites and 3.5% in African Americans, but it was absent in Hispanics. Inferring haplotypes using PHASE, version 2.1, the greatest haplotype diversity was observed in African Americans followed by non-Latino whites and Hispanics. Haplotype 2A and 2B, consisting of a hypermorphic promoter SNP cluster (-2650C>G, -2543T>A, and -2177G>C) in linkage with synonymous structural variants was inferred at a frequency of 27% in the Hispanic population, but only 5% in non-Latino whites and African Americans. This same promoter SNP cluster in linkage with one or more hypomorphic structural variant also was inferred in multiple haplotypes at a total frequency of 5.6% in the African-American study group but less than 1% in the other two groups. The sum frequencies of the hypomorphic haplotypes H3 [15,167G>A (E158K)], H5B [-2650C>G, 15,167G>A (E158K), 21,375C>T (N285N), 21,443A>G (E308G)], and H6 [15,167G>A (E158K), 21,375C>T (N285N)] was 28% in Hispanics, 23% in non-Latino whites, and 24% in African Americans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050781     DOI: 10.1124/jpet.106.112268

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.

Authors:  Leticia B A Rangel; Jodi L Taraba; Christopher R Frei; Lon Smith; Gladys Rodriguez; John G Kuhn
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

2.  Clinical utility gene card for: trimethylaminuria.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2011-11-30       Impact factor: 4.246

3.  Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver.

Authors:  Trine Celius; Andrea Pansoy; Jason Matthews; Allan B Okey; Marilyn C Henderson; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-04       Impact factor: 4.219

4.  Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.

Authors:  Jin Won Sung; Hwi-Yeol Yun; Sunny Park; Young Ju Kim; Jeong Yee; Kyung Eun Lee; Byungjeong Song; Jee Eun Chung; Hye Sun Gwak
Journal:  Pharm Res       Date:  2020-01-28       Impact factor: 4.200

5.  Joint functions of protein residues and NADP(H) in oxygen activation by flavin-containing monooxygenase.

Authors:  Roberto Orru; Daniel E Torres Pazmiño; Marco W Fraaije; Andrea Mattevi
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

6.  Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects.

Authors:  Derrek P Hibar; Jason L Stein; April B Ryles; Omid Kohannim; Neda Jahanshad; Sarah E Medland; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Andrew J Saykin; Clifford R Jack; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2013-06       Impact factor: 3.978

7.  Modeling effects of human single nucleotide polymorphisms on protein-protein interactions.

Authors:  Shaolei Teng; Thomas Madej; Anna Panchenko; Emil Alexov
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

8.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

9.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Authors:  Sharon K Krueger; Marilyn C Henderson; Lisbeth K Siddens; Jonathan E VanDyke; Abby D Benninghoff; P Andrew Karplus; Bjarte Furnes; Daniel Schlenk; David E Williams
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

Review 10.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.